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Summary.-An immunoadsorbent technique is described whereby tumour-specific
antibodies may be isolated. Extracts from normal human lung tissue were pooled
and bound to cyanogen bromide activated Sepharose 4B. Antisera raised in rabbits
to a variety of extracts from human bronchogenic carcinoma were passed through
these immunoadsorbent columns to yield antisera specific for tumour-associated
antigens as demonstrated by immunodiffusion and immunoelectrophoresis.
THERE is considerable interest in the
possible presence on tumour cells of anti-
gens not present on normal cells, and in
the possible application of these antigens
for diagnostic, prognostic, or immuno-
therapeutic purposes. A large body of
evidence exists at this time supporting
the probability that a majority ofpatients
with neoplastic disease mount a cell-
mediated immune response to antigens
present on their tumour cells. This has
been demonstrated with patient's lym-
phocytes by a variety of in vitro assays
for cell-mediated immunity (Mavligit et al.,
1973, Gutterman et al., 1972, Segall et al.,
1972, and Hellstr6m et al., 1969) in the
presenceofautochthonous tumour extracts
or cell preparations. In some instances,
the patient's lymphocytes will undergo
blastogenesis in the presence of extracts
from allogeneic, but similar tumours
(Segall et al., 1972) indicating the presence
of common tumour antigens associated
with certain types of tumours. The
actual demonstration of tumour associa-
ted antigens has been achieved in a variety
of ways which include neonatal toleriza-
tion of rabbits with normal cell prepara-
tions and subsequent immunization with
tumour cells or extracts (Gold and
Freedman, 1965) as was the case with
15
carcinoembryonic antigen, or immuniza-
tion of experimental animals with tumour
extracts with subsequent absorption of
the antiserum with normal tissue prepara-
tions (Battacharya and Barlow, 1973,
and Yachi et al., 1968). The main
problem associated with the demon-
stration of tumour associated antigens in
extracts from tumour cells lies in the
apparent very low concentration of these
antigens compared with the great pre-
ponderance of normal antigens, so that
hyperimmunization of experimental ani-
mals may be necessary before a measur-
able immune response to the tumour
specific materials can be demonstrated.
We have found that hyperimmunization
of animals rendered tolerant frequently
leads to a breakdown of tolerance to
normal components, and tissue absorp-
tion with hyperimmune serum is fre-
quently unsuccessful in the removal of
all the normal antibody. Also, both of
these techniques are found to be time
consuming, and involve the use of large
amounts oftissue.
The present preliminary communica-
tion describes an immunoadsorbent tech-
nique whereby a single step procedure
may be used for the preparation oftumour-
specific antiserum active against extractsR. D. WATSON, A. G. SMITH AND J. G. LEVY
prepared from suspensions of broncho-
genic carcinoma cells.
MATERIALS AND METHODS
Extracts were made from both carcinoma
and normal lung tissue (taken at postmortem
from individuals dying from non-malignant
causes) by teasing apart the cells and agitat-
ing them gently at 4°C for 18 h in a 3 0 mol/l
KCI solution, according to the procedure
used by Reisfeld, Pellegrino and Kahan
(1971) for the extraction ofhistocompatibility
antigens. The extracts were centrifuged
at 20,000 g for 90 min at 4°C. The soluble
material was dialysed exhaustively against
physiological saline at 4°C after which it was
again centrifuged and either sterilized by
Millipore filtration or frozen until required.
The protein content of the extracts was
calculated by the standard Lowry technique.
Randomly bred adult albino rabbits were
immunized with repeated injections oftumour
extracts in 5000 complete Freund's adjuvant
(Difco). Inoculations were administered sub-
cutaneously in 0-2 ml quantities in 5 sites
at each immunization. Injections were given
at weekly intervals over an 8 week period
after which time the animals were bled by
cardiac puncture and the serum was collected,
inactivated at 56°C for 30 min, and stored
frozen. A total of 10 mg of protein was
administered at each weekly immunization
session.
Extracts from eight normal lungs were
pooled in order to prepare the immuno-
adsorbent. The pooled extract was dialysed
at 4°C against 0-2 mol/l borate buffer at
pH 8-45 in 0 3 mol/l NaCl. Conjugation of
the pooled extract was carried out by a
modification of the procedure described
originally by Porath, Axen and Ernback
(1967). Sepharose 4B (Pharmacia) was
washed extensively in distilled water in a
Buchner funnel before it was transferred as a
thick aqueous slurry to a beaker and was;
adjusted to pH 11-3 with 50 N NaOH. A
ratio of 6 mg of protein per 1 0 ml of
packed Sepharose was used for the coupling.
Cyanogen bromide (Eastman) was dissolved
in distilled water at a concentration of 25 mg/
ml, and the Sepharose was activated by
adding the cyanogen bromide to it at a con-
centration of 40 mg/ml of packed Sepharose.
The pH was maintained at 11 3 with 5 0 N
NaOH until the pH became stabilized
(usually 10-15 min). The Sepharose was
then washed rapidly Nit,h several volumes of
ice cold distilled water and finally with ice
cold borate buffer.
The Sepharose was then transferred to a
reaction vessel, along w%ith the protein to be
conjugated. The vessel was sealed and left
for 18 h at 4°C under gentle agitation (by
rocking or slow end-over-end rotation).
The Sepharose was then transferred to a
jacketed Pharmacia column and washed in
the follow,ing manner:
-three column volumes ofborate buffer
three column volumes of tris-HCl-
NaCl buffer at pH 7-6 (01 mol/l tris,
0 4 mol/l NaCl)
three column volumes of 0-25 mol/l
acetic acid
-three column volumes of tris buffer at
pH 7-6.
The columns were cooled by running tap
water (85-10°C) through the jacket.
Heat inactivated rabbit antiserum to a
number of extracts made from bronchogenic
carcinoma specimens were pumped, with an
LKB peristaltic pump through the column,
in 2 or 4 ml quantities, and flushed with the
pH 7-6 tris buffer. Columns were run at
15 ml/h, the eluent collected in an LKB
fraction collector, and the tubes read spectro-
photometrically for 280 nm absorbance. The
tubes containing the eluted serum were
pooled and concentrated to their original
volume by ultrafiltration on a Diaflo XM1OOA
ultrafiltration membrane. The antibody was
mainly tumour specific. The ' anti-normal "
components of the antisera w-ere eluted from
the column with 0 25 mol/l acetic acid. The
eluted antibody w%ras neutralized by placing
2 ml of saturated NaHCO3 into each tube
before collection of 10 ml fractions, and con-
centrated and washed with tris-HCl buffer by
ultrafiltration. All preparations were stored
frozen at -20°C. The immuno-adsorbent
columns were regenerated by washing them
with tris buffer, and have been found to be
re-usable for at least 10 runs, although the
capacity decreases.
Theantisera weretestedbyeitherimmuno-
diffusion in agar on glass slides against both
normal tissue and tumour extracts, or by
immunoelectrophoresis.
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FIG. 1.-Immunodiffusion ofwhole, absorbed
and eluted antiserum raised against the
tumour extract C-26. (a) Centre well;
whole antiserum against a- tumour extract
(C-26) (1) C-26 extract (2) pooled extract
fromnormal lung (N); (3) to (6) four tumour
extracts (C-30, C-40, C-24 and C-41). (b)
Centre well; absorbed anti C-26; (1) C-26
extract, (2) N-extract, (3) C-24 extract, (4)
C-40 extract, (5) partially purified C-26
extract, (6) individual normal lung extract
(N-50). (c) Centre well; eluted "anti-
normal " serum from anti C-26; (1) C-26
extract, (2) N-extract, (3) C-30 extract;
(4) C-40 extract, (5) C-24 extract, (6) C-41
extract. The plates were washed, dried















FiG. 2.-Immunoelectrophoresis of whole and absorbed antisera to tumour extracts. (a) Pattern
of whole antiserum to tumour extract C-40. The upper well (1) contains a pooled extract of
normal lung (N) and the lower (2) contains C-40 extract. (b) Absorbed anti-C-40 serum run
against N (well 1) and C-40 (well 2). While incomplete absorption is shown by the faint line in
the upper area, the tumour extract demonstrates the presence of three distinct bands, very close
to each other. (c) Pattern of absorbed anti C-26 run against N (well 1) and C-26 (well 2).ISOLATION OF TUMOUR SPECIFIC ANTIBODIES
RESULTS
This procedure has enabled us, in
essentially one step, to remove from the
serum of rabbits immunized with tumour
extracts, 90 to 100% of the antibodies
directed to normal lung antigens. Repre-
sentative pictures of immunodiffusion
and immunoelectrophoresis studies car-
ried out with whole, absorbed and eluted
antisera are shown on Fig. 1 and 2.
Fig. 1 demonstrates a successfully ab-
sorbed serum. In this instance, the eluted
antibody appeared to react with three
tumour antigens not found in normal
extracts (well 5, Fig. 1(b)). It should be
mentioned that the absorption of antisera
was not always as complete as that
demonstrated here. However, even when
some " anti-normal " antibodies remained
in the test material, the predominant
species were always anti-tumour, and
could be readily distinguished. Fig. 2
demonstrates the results of immuno-
electrophoresis of two different tumour
extracts. We have observed that anti-
tumour antisera frequently appeared to
contain only one antibody species when
tested by immunodiffusion, and subse-
quently-demonstrated two or three when
tested by immunoelectrophoresis (Fig.
2(b)).
A number of bronchogenic carcinoma
extracts have been tested for tumour
associated materials (antigenic in rabbits)
in this way. Preliminary studies demon-
strate that common antigens exist in
some tumour extracts (Fig. 3), and that
these antigens are not present in any of
the normal extracts so far tested. Fig. 3
demonstrates cross-reactivity between two
carcinoma extracts (C-26 and C-30). In
this instance C-30 apparently contains an
antigen common to only one of the three
antigens seen in C-26. A study is under
way to investigate a wide panel of both
tumour and normal lung extracts to deter-
mine the degree of cross-reactivity of
tumour antigens, and to ensure that these
are not found in normal tissue.
DISCUSSION








FIG. 3. Immunodiffusion with tumour-specific antiserum to C-26 (centre well) and a variety of
tumour extracts. (1) C-26, (2) C-30, (3) C-40, (4) C-24, (5) C-6, (6) N. It can be seen that C-30
shares identity with one of the three tumour-specific components of C-26
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is to present a new procedure whereby
the difficult area of isolation and identifi-
cation of tumour-associated antigens may
be somewhat facilitated. The data pres-
ented in no way represent a study of
antigens associated with bronchogenic
carcinoma but have been used to demon-
strate the feasibility of the immuno-
adsorbent technique, and to demonstrate
that partial cross-reactivity appears to
exist between some carcinoma extracts.
A large programme of work is currently
under way to study the extent of this
cross-reactivity and to determine whether
or not common antigens are associated
with histologically similar tumour
specimens.
It is recognized that the methods used
here to detect tumour-associated antigens
are not as sensitive as others such as the
radioimmunoassay or immunofluorescent
techniques. The ultimate purpose of this
work is to isolate these antigens so that
they may be used for further screening
tests. Thus, highly sensitive detection
methods at this stage are not necessary.
It is possible that many of the appar-
ently tumour-specific components demon-
strated by the procedures described here
may merely represent increased produc-
tion of certain normal components by
tumour cells. Further studies will involve
investigation of this possibility, as well as
investigation of whether or not these
components represent immunologically
active materials in humans.
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